This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Paulino, A. C. Articles by Reddy, S. P. Search for Related Content PubMed PubMed Citation Articles by Paulino, A. C. Articles by Reddy, S. P. Social Bookmarking                         What's this?

Splenic irradiation in the palliation of patients with lymphoproliferative and myeloproliferative disorders

Department of Radiotherapy, Loyola University of Chicago, Stritch School of Medicine, Maywood, Illinois, Edward Hines Jr. Hospital, Hines, Illinois

Sarada P. Reddy, MD

Department of Radiotherapy, Loyola University of Chicago, Stritch School of Medicine, Maywood, Illinois, Edward Hines Jr. Hospital, Hines, Illinois

Introduction: Splenic irradiation is an accepted mode of treatment for palliation of hypersplenism and splenic pain for patients with lymphoproliferative or myeloproliferative disorders. However, results are conflicting regarding the duration of palliation and the toxicity associated with this treatment.

Methods: Twenty-five patients with lymphoproliferative or myeloproliferative disorders were treated with splenic irradiation for palliation of splenomegaly and pain. The spleen was measured and pain and toxicity were assessed during radiation therapy.

Results: Splenomegaly and splenic pain decreased in 60 percent and 91 percent of patients, respectively. Radiation doses higher than 500 cGy appeared to be more effective than lower doses in reducing the spleen size in patients with chronic lymphocytic leukemia. Regression of splenomegaly and pain relief were maintained for less than one year and more than six months, respectively. Acute radiation toxicity resulted in the cessation of radiotherapy in two patients.

Conclusion: Splenic irradiation is effective in the short-term palliation of splenomegaly and pain and may be most useful in the subset of patients with a life expectancy of less than one year. Terminally ill patients with splenomegaly secondary to lymphoproliferative or myeloproliferative disorders may benefit from splenic irradiation to minimize pain and pressure symptoms in addition to possible reduction of narcotic use.

American Journal of Hospice and Palliative Medicine®, Vol. 13, No. 6, 32-35 (1996)
DOI: 10.1177/104990919601300613


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?